DURATION OF SKIN PHOTOSENSITIVITY AND INCIDENCE OF PHOTOSENSITIVITY REACTIONS AFTER ADMINISTRATION OF VERTEPORFIN
- 1 December 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health
- Vol. 22 (6) , 691-697
- https://doi.org/10.1097/00006982-200212000-00002
Abstract
Verteporfin (Visudyne, Novartis AG) is a light-activated drug that reduces the risk of vision loss in patients with certain types of choroidal neovascularization (CNV). Because photosensitivity can occur with photosensitizers, it is important for ophthalmologists providing verteporfin therapy to understand its time course and duration, as well as the incidence of photosensitivity reactions. Data were obtained from three sources: 1) the time course of skin photosensitivity in 17 volunteers by measuring erythema/edema over time after verteporfin, using red light exposure; 2) the duration of skin photosensitivity in 30 patients with skin cancer by exposing skin to simulated solar light and calculating the daily minimal erythematous dose; and 3) the incidences of photosensitivity reactions as recorded in three phase III trials in patients with CNV secondary to age-related macular degeneration or pathologic myopia who received the regimen of verteporfin therapy currently approved by regulatory authorities (infusion of 6 mg/m2 body surface area). 1) Skin photosensitivity was high at the first timepoint of 1.5 hours after dosing and decreased rapidly thereafter; 2) the duration of skin photosensitivity was dose dependent, ranging from 2.0 to 6.7 days at 6 to 20 mg/m2, respectively (mean of 2 days at a dose of 6 mg/m2); and 3) photosensitivity reactions occurred in only 2.2% of patients in the phase III trials, including two severe events, one secondary to extravasation. All treatment-related reactions in the phase III trials occurred within the first 2 days after dosing, with the exception of two mild reactions and one moderate reaction that occurred 3 days after treatment. Verteporfin is associated with short-lived photosensitivity and a low incidence of photosensitivity reactions in clinical trials, most of which could probably have been avoided by adherence to protocol instructions for skin protection.Keywords
This publication has 8 references indexed in Scilit:
- Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: One-year results of an uncontrolled, prospective case seriesOphthalmology, 2002
- Clinical Pharmacokinetics of VerteporfinThe Journal of Clinical Pharmacology, 2002
- GUIDELINES FOR USING VERTEPORFIN (VISUDYNE®) IN PHOTODYNAMIC THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSESRetina, 2002
- Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfinOphthalmology, 2001
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2American Journal of Ophthalmology, 2001
- A Preliminary Pharmacokinetic Study of Intravenous Photofrin® in PatientsJournal of Clinical Laser Medicine & Surgery, 1996
- PHOTOPHYSICAL AND PHOTOSENSITIZING PROPERTIES OF BENZOPORPHYRIN DERIVATIVE MONOACID RING A (BPD‐MA)*Photochemistry and Photobiology, 1994
- Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivativeLasers in Surgery and Medicine, 1988